California Institute for Regenerative Medicine (CIRM)
@cirmnews.bsky.social
CIRM's mission is to accelerate world-class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and world. Visit our website at cirm.ca.gov.
The official CIRM account.
The official CIRM account.
Pinned
CIRM’s 2025 Annual Report, Looking Forward: Advancing California’s Scientific Vision, is now available. It highlights #ScientificProgress, patient stories, and efforts to expand access to #RegenerativeMedicine across California.
Explore it here: https://adobe.ly/42FSVed
Explore it here: https://adobe.ly/42FSVed
Access to clinical trials shouldn’t depend on where you live. CIRM is investing $27M to establish three Community Care Centers of Excellence in South LA, the Inland Empire & Desert Region, & the Central Valley—bringing stem cell & gene therapy trials closer to home. For more: https://bit.ly/3Wwl4Rq
October 30, 2025 at 5:45 PM
Access to clinical trials shouldn’t depend on where you live. CIRM is investing $27M to establish three Community Care Centers of Excellence in South LA, the Inland Empire & Desert Region, & the Central Valley—bringing stem cell & gene therapy trials closer to home. For more: https://bit.ly/3Wwl4Rq
Yael Wyte has spent 20+ years advocating for people with #Alzheimers. Now, as a CIRM Board member, she’s helping advance #RegenerativeMedicine with compassion and purpose.
Read her full story: https://bit.ly/48HhD1B
Read her full story: https://bit.ly/48HhD1B
October 22, 2025 at 3:30 PM
Yael Wyte has spent 20+ years advocating for people with #Alzheimers. Now, as a CIRM Board member, she’s helping advance #RegenerativeMedicine with compassion and purpose.
Read her full story: https://bit.ly/48HhD1B
Read her full story: https://bit.ly/48HhD1B
Backed by early CIRM funding, a @uclastemcell.bsky.social-led gene therapy for a deadly childhood immune condition appears successful and has achieved success with 95% of the children in the trial regaining full functioning immune systems.
Read more: nbcnews.to/46Wd81X
Read more: nbcnews.to/46Wd81X
Exposure to any germs could've killed her. 11 years later, she's living a normal life thanks to a gene therapy treatment.
New research found that gene therapy for children with a form of severe combined immunodeficiency was successful in 95% of trial participants.
nbcnews.to
October 17, 2025 at 5:37 PM
Backed by early CIRM funding, a @uclastemcell.bsky.social-led gene therapy for a deadly childhood immune condition appears successful and has achieved success with 95% of the children in the trial regaining full functioning immune systems.
Read more: nbcnews.to/46Wd81X
Read more: nbcnews.to/46Wd81X
CIRM’s 2025 Annual Report, Looking Forward: Advancing California’s Scientific Vision, is now available. It highlights #ScientificProgress, patient stories, and efforts to expand access to #RegenerativeMedicine across California.
Explore it here: https://adobe.ly/42FSVed
Explore it here: https://adobe.ly/42FSVed
October 16, 2025 at 3:30 PM
CIRM’s 2025 Annual Report, Looking Forward: Advancing California’s Scientific Vision, is now available. It highlights #ScientificProgress, patient stories, and efforts to expand access to #RegenerativeMedicine across California.
Explore it here: https://adobe.ly/42FSVed
Explore it here: https://adobe.ly/42FSVed
Behind every breakthrough is years of science. Kim Barrett, PhD, says @ucdavishealth.bsky.social CuRe Trial for spina bifida was possible thanks to early studies funded by CIRM’s Discovery program. Investing across the pipeline turns discoveries into therapies.
Learn more: https://bit.ly/3W2nUNF
Learn more: https://bit.ly/3W2nUNF
October 1, 2025 at 3:30 PM
Behind every breakthrough is years of science. Kim Barrett, PhD, says @ucdavishealth.bsky.social CuRe Trial for spina bifida was possible thanks to early studies funded by CIRM’s Discovery program. Investing across the pipeline turns discoveries into therapies.
Learn more: https://bit.ly/3W2nUNF
Learn more: https://bit.ly/3W2nUNF
Adrienne Shapiro, a 4th-generation mother of children with sickle cell disease, has been a tireless advocate for stem cell research and a powerful patient voice at CIRM. Her efforts helped advance a groundbreaking trial at @uclastemcell.bsky.social.
Read her story: https://bit.ly/3VAQfKY
Read her story: https://bit.ly/3VAQfKY
September 26, 2025 at 3:30 PM
Adrienne Shapiro, a 4th-generation mother of children with sickle cell disease, has been a tireless advocate for stem cell research and a powerful patient voice at CIRM. Her efforts helped advance a groundbreaking trial at @uclastemcell.bsky.social.
Read her story: https://bit.ly/3VAQfKY
Read her story: https://bit.ly/3VAQfKY
“Discovery research is critical for uncovering novel disease targets and biomarkers that we can translate into therapies for clinical use,” said Kelly Shepard, PhD, Director of Discovery & Education programs at CIRM.
Read the full announcement: https://bit.ly/4gDLREC
Read the full announcement: https://bit.ly/4gDLREC
September 25, 2025 at 11:12 PM
“Discovery research is critical for uncovering novel disease targets and biomarkers that we can translate into therapies for clinical use,” said Kelly Shepard, PhD, Director of Discovery & Education programs at CIRM.
Read the full announcement: https://bit.ly/4gDLREC
Read the full announcement: https://bit.ly/4gDLREC
Evie Junior, born with #SickleCellDisease, participated in a CIRM-funded clinical trial at @uclastemcell.bsky.social, using his own modified stem cells. He’s now free from pain crises and meds.
This #SickleCellAwarenessMonth, we highlight the promise of curative therapies. https://bit.ly/47YO3o6
This #SickleCellAwarenessMonth, we highlight the promise of curative therapies. https://bit.ly/47YO3o6
September 24, 2025 at 3:30 PM
Evie Junior, born with #SickleCellDisease, participated in a CIRM-funded clinical trial at @uclastemcell.bsky.social, using his own modified stem cells. He’s now free from pain crises and meds.
This #SickleCellAwarenessMonth, we highlight the promise of curative therapies. https://bit.ly/47YO3o6
This #SickleCellAwarenessMonth, we highlight the promise of curative therapies. https://bit.ly/47YO3o6
Babies with spina bifida are growing into walking, healthy toddlers thanks to a CIRM-funded trial at @ucdavishealth.bsky.social. Board member Kim Barrett shares why this work brings real hope.
Read the full story: https://bit.ly/3W2nUNF
Read the full story: https://bit.ly/3W2nUNF
September 23, 2025 at 4:56 PM
Babies with spina bifida are growing into walking, healthy toddlers thanks to a CIRM-funded trial at @ucdavishealth.bsky.social. Board member Kim Barrett shares why this work brings real hope.
Read the full story: https://bit.ly/3W2nUNF
Read the full story: https://bit.ly/3W2nUNF
When Kim Barrett joined CIRM’s board in 2021, she called it “an awesome responsibility.” Now Vice Dean for Research at @ucdavis.bsky.social, she helps guide how California invests in regenerative medicine.
“An awesome responsibility”: A conversation with CIRM board member Kim Barrett
Written by Holly Alyssa MacCormick It’s not every day that you get to contribute to something that could help save a life, but when Kim Barrett joined the board of the California Institute for Rege…
blog.cirm.ca.gov
September 19, 2025 at 3:30 PM
When Kim Barrett joined CIRM’s board in 2021, she called it “an awesome responsibility.” Now Vice Dean for Research at @ucdavis.bsky.social, she helps guide how California invests in regenerative medicine.
CIRM-funded @uclastemcell.bsky.social researchers reprogrammed blood #StemCells to produce #cancer-targeting T cells—offering a renewable path for immunotherapy. Early results are promising for treatment-resistant tumors.
#BlueskyBiotech
#BlueskyBiotech
UCLA scientists reprogram stem cells to create renewable cancer-fighting T cells
In a first-of-its-kind clinical trial, UCLA scientists have shown it’s possible to reprogram a patient’s blood-forming stem cells to generate a continuous supply of functional T cells, the immune syst...
stemcell.ucla.edu
September 10, 2025 at 4:20 PM
CIRM-funded @uclastemcell.bsky.social researchers reprogrammed blood #StemCells to produce #cancer-targeting T cells—offering a renewable path for immunotherapy. Early results are promising for treatment-resistant tumors.
#BlueskyBiotech
#BlueskyBiotech
Maya Singh, a CIRM COMPASS trainee from @ucberkeleyofficial.bsky.social, helped advance #CancerResearch and gained key skills for med school. Now at Tuoro University California, she credits the COMPASS program for shaping her path.
blog.cirm.ca.gov/2025/08/27/c...
blog.cirm.ca.gov/2025/08/27/c...
September 9, 2025 at 4:42 PM
Maya Singh, a CIRM COMPASS trainee from @ucberkeleyofficial.bsky.social, helped advance #CancerResearch and gained key skills for med school. Now at Tuoro University California, she credits the COMPASS program for shaping her path.
blog.cirm.ca.gov/2025/08/27/c...
blog.cirm.ca.gov/2025/08/27/c...
Kidney cancer is among the top 10 most common cancers in the US.
With support from CIRM funding, @uclahealth.org researchers are developing AlloCAR70-NKT—an “off-the-shelf” stem cell–derived immunotherapy that targets tumors and reprograms their environment.
With support from CIRM funding, @uclahealth.org researchers are developing AlloCAR70-NKT—an “off-the-shelf” stem cell–derived immunotherapy that targets tumors and reprograms their environment.
UCLA scientists develop off-the-shelf immunotherapy for metastatic kidney cancer
UCLA researchers have developed a new kind of immunotherapy that uses specially engineered immune cells equipped with built-in weapons to attack kidney cancer tumors and reprogram their protective env...
www.uclahealth.org
September 4, 2025 at 10:30 PM
Kidney cancer is among the top 10 most common cancers in the US.
With support from CIRM funding, @uclahealth.org researchers are developing AlloCAR70-NKT—an “off-the-shelf” stem cell–derived immunotherapy that targets tumors and reprograms their environment.
With support from CIRM funding, @uclahealth.org researchers are developing AlloCAR70-NKT—an “off-the-shelf” stem cell–derived immunotherapy that targets tumors and reprograms their environment.
Hope drives Beast Games winner Jeffrey Allen, whose son has creatine transporter deficiency. At the #CIRMTraineeConference, he urged researchers to connect with patients. CIRM is funding @uclahealth.org's $2.3M gene therapy project for CTD and other #RareDiseases.
#BioSky #MedSky #Biotech #EduSky
#BioSky #MedSky #Biotech #EduSky
Jeffrey Randall Allen Champions CTD Research to Help His Son
Beast Games winner Jeffrey Allen is using his $10 million prize to fund research for his son’s rare genetic disorder, creatine transporter deficiency (CTD). Speaking at the 2025 CIRM Trainee Networkin...
blog.cirm.ca.gov
August 15, 2025 at 4:47 PM
Hope drives Beast Games winner Jeffrey Allen, whose son has creatine transporter deficiency. At the #CIRMTraineeConference, he urged researchers to connect with patients. CIRM is funding @uclahealth.org's $2.3M gene therapy project for CTD and other #RareDiseases.
#BioSky #MedSky #Biotech #EduSky
#BioSky #MedSky #Biotech #EduSky
Thank you to all the incredible trainees, program directors, patient advocates, and inspiring speakers who joined us for the 2025 #CIRMTraineeConference!
We’re grateful for the insights you shared and the community we continue to build together in advancing #RegenerativeMedicine. #BlueskyBiotech
We’re grateful for the insights you shared and the community we continue to build together in advancing #RegenerativeMedicine. #BlueskyBiotech
July 30, 2025 at 8:13 PM
Thank you to all the incredible trainees, program directors, patient advocates, and inspiring speakers who joined us for the 2025 #CIRMTraineeConference!
We’re grateful for the insights you shared and the community we continue to build together in advancing #RegenerativeMedicine. #BlueskyBiotech
We’re grateful for the insights you shared and the community we continue to build together in advancing #RegenerativeMedicine. #BlueskyBiotech
It’s great to hear about the various career paths in the #RegenerativeMedicine field—from R&D and lab work to policy and #SciComms. Thank you to our panelists for sharing their experiences and insights. #CIRMTraineeConference
July 28, 2025 at 5:26 PM
It’s great to hear about the various career paths in the #RegenerativeMedicine field—from R&D and lab work to policy and #SciComms. Thank you to our panelists for sharing their experiences and insights. #CIRMTraineeConference
We couldn’t agree more! CIRM proudly supports the next generation of scientists through education and training programs that advance stem cell research and regenerative medicine. Enjoy connecting and sharing your journey! #NextGenStemCell #STEMeducation #CAworkforce
Excited to network, exchange and communicate my experience and research. The trainee conference is unique and special to all trainees and mentors in the stem cell research field 😍 #CIRM #LA #CIRMconference #UCSC #trainee #mentor @cirmnews.bsky.social
July 28, 2025 at 4:30 PM
We couldn’t agree more! CIRM proudly supports the next generation of scientists through education and training programs that advance stem cell research and regenerative medicine. Enjoy connecting and sharing your journey! #NextGenStemCell #STEMeducation #CAworkforce
CIRM supports hands-on research training for students of all education levels. These highly trained students help power California’s $414 billion #LifeSciences industry and bring new treatments closer to patients.
Learn more about how we’re investing in people, and not just science. #BlueskyBiotech
Learn more about how we’re investing in people, and not just science. #BlueskyBiotech
20 Years of CIRM: Building the Workforce
In celebration of the California Institute for Regenerative Medicine (CIRM)’s 20th anniversary, we have been reflecting on some of the early projects we supported and their outcomes.Today, we’re lo…
blog.cirm.ca.gov
July 21, 2025 at 4:38 PM
CIRM supports hands-on research training for students of all education levels. These highly trained students help power California’s $414 billion #LifeSciences industry and bring new treatments closer to patients.
Learn more about how we’re investing in people, and not just science. #BlueskyBiotech
Learn more about how we’re investing in people, and not just science. #BlueskyBiotech
Creatine Transporter Deficiency (CTD) is a rare brain disorder with no cure—yet. But families like Jeffrey Randall Allen’s are fighting for a future where gene therapy changes everything. [1/3]
July 18, 2025 at 4:28 PM
Creatine Transporter Deficiency (CTD) is a rare brain disorder with no cure—yet. But families like Jeffrey Randall Allen’s are fighting for a future where gene therapy changes everything. [1/3]
Millions live with painful osteoarthritis worldwide. A CIRM-funded clinical trial by Genascence reported positive early results using a gene therapy approach, demonstrating safety and sustained efficacy at 12 months.
Learn more on our blog at bit.ly/4nzlpzb
#BlueskyBiotech #Science #ClinicalTrials
Learn more on our blog at bit.ly/4nzlpzb
#BlueskyBiotech #Science #ClinicalTrials
July 8, 2025 at 7:28 PM
Millions live with painful osteoarthritis worldwide. A CIRM-funded clinical trial by Genascence reported positive early results using a gene therapy approach, demonstrating safety and sustained efficacy at 12 months.
Learn more on our blog at bit.ly/4nzlpzb
#BlueskyBiotech #Science #ClinicalTrials
Learn more on our blog at bit.ly/4nzlpzb
#BlueskyBiotech #Science #ClinicalTrials
Most ALS cases have no known genetic cause. With CIRM support, Julia Kaye, PhD, at @gladstoneinst.bsky.social, is using patient-derived #StemCells to uncover disease mechanisms and test potential therapies for sporadic #ALS.
#RareDiseases #Science #Biotech #RegenerativeMedicine
#RareDiseases #Science #Biotech #RegenerativeMedicine
How Patient-Derived Cells Are Changing ALS Research
Research Investigator Julia Kaye, PhD, stands for a portrait in a lab at Gladstone Institutes. Photo courtesy of Gladstone Institutes. Before there can be any therapies for disease, scientists need…
blog.cirm.ca.gov
July 2, 2025 at 5:54 PM
Most ALS cases have no known genetic cause. With CIRM support, Julia Kaye, PhD, at @gladstoneinst.bsky.social, is using patient-derived #StemCells to uncover disease mechanisms and test potential therapies for sporadic #ALS.
#RareDiseases #Science #Biotech #RegenerativeMedicine
#RareDiseases #Science #Biotech #RegenerativeMedicine
A #GeneTherapy trial for rare immune disorder LAD-I, developed by Rocket Pharmaceuticals and co-led by @uclastemcell.bsky.social, with support from a $5.8M CIRM grant, restored immune function in all 9 children treated—marking a major step forward in gene therapy.
#RegenerativeMedicine #RareDisease
#RegenerativeMedicine #RareDisease
Gene therapy restores immune function and extends lives of children with rare immune disorder
An investigational gene therapy has successfully restored immune function in all nine children treated with the rare and life-threatening immune disorder called severe leukocyte adhesion deficiency-I,...
stemcell.ucla.edu
June 26, 2025 at 7:01 PM
A #GeneTherapy trial for rare immune disorder LAD-I, developed by Rocket Pharmaceuticals and co-led by @uclastemcell.bsky.social, with support from a $5.8M CIRM grant, restored immune function in all 9 children treated—marking a major step forward in gene therapy.
#RegenerativeMedicine #RareDisease
#RegenerativeMedicine #RareDisease
The next generation of #scientists are being trained in #California, and they're making a difference.
Through the CIRM Bridges program at CSU Northridge, undergraduates are contributing to groundbreaking #StemCellResearch while preparing for careers in #RegenerativeMedicine and beyond. #biosky
Through the CIRM Bridges program at CSU Northridge, undergraduates are contributing to groundbreaking #StemCellResearch while preparing for careers in #RegenerativeMedicine and beyond. #biosky
Building Bridges to Careers in Health — and Regenerative Medicine - CSUN Newsroom
Through the CIRM Bridges CSUN Stem Cell Research and Therapy Training Program, students search for scientific breakthroughs.
newsroom.csun.edu
June 25, 2025 at 10:20 PM
The next generation of #scientists are being trained in #California, and they're making a difference.
Through the CIRM Bridges program at CSU Northridge, undergraduates are contributing to groundbreaking #StemCellResearch while preparing for careers in #RegenerativeMedicine and beyond. #biosky
Through the CIRM Bridges program at CSU Northridge, undergraduates are contributing to groundbreaking #StemCellResearch while preparing for careers in #RegenerativeMedicine and beyond. #biosky
Backed by a $14 million CIRM award, Neurona Therapeutics is advancing a stem cell therapy that could transform epilepsy treatment without surgery or tissue damage. Learn more on our blog: blog.cirm.ca.gov/2025/06/20/n...
#neuroskyence #blueskybiotech #epilepsy #regenerativemedicine
#neuroskyence #blueskybiotech #epilepsy #regenerativemedicine
June 20, 2025 at 9:07 PM
Backed by a $14 million CIRM award, Neurona Therapeutics is advancing a stem cell therapy that could transform epilepsy treatment without surgery or tissue damage. Learn more on our blog: blog.cirm.ca.gov/2025/06/20/n...
#neuroskyence #blueskybiotech #epilepsy #regenerativemedicine
#neuroskyence #blueskybiotech #epilepsy #regenerativemedicine
🚨 REMINDER: Prospective DISC4 applicants, the Pre-Submission Form deadline is June 16 at 2 PM.
The DISC4 Awards support large, cross-disciplinary teams working on innovative ways to understand and treat human disease. Learn more at www.cirm.ca.gov/disc4/.
The DISC4 Awards support large, cross-disciplinary teams working on innovative ways to understand and treat human disease. Learn more at www.cirm.ca.gov/disc4/.
June 12, 2025 at 8:13 PM
🚨 REMINDER: Prospective DISC4 applicants, the Pre-Submission Form deadline is June 16 at 2 PM.
The DISC4 Awards support large, cross-disciplinary teams working on innovative ways to understand and treat human disease. Learn more at www.cirm.ca.gov/disc4/.
The DISC4 Awards support large, cross-disciplinary teams working on innovative ways to understand and treat human disease. Learn more at www.cirm.ca.gov/disc4/.